Polaris Market Research releases its new research report on the minimal residual disease (MRD) market, which provides comprehensive insight into the current market landscape and future outlook. It discusses the major forces driving growth, including the rising global cancer burden, the shift toward precision oncology, and continuing advances in next-generation sequencing (NGS) and liquid biopsy technologies. The report studies the effect of rising demand, technology, applications, investments, and competition, offering insight into how the market is likely to shape up across segments and geographies through 2034.

Minimal Residual Disease (MRD) Market at a Glance

Understanding the Minimal Residual Disease (MRD) Market

Minimal residual disease (MRD) testing detects the small number of cancer cells that remain in a patient's body after treatment, using highly sensitive methods such as flow cytometry, PCR, and next-generation sequencing. Primarily applied in blood cancers like leukemia, lymphoma, and multiple myeloma, MRD results help clinicians assess treatment response, estimate relapse risk, and guide post-treatment monitoring decisions.

What Are the Major Factors Influencing the Market?

The minimal residual disease industry is shaped by several forces that affect demand, adoption, investment, innovation, and competitive intensity. The dynamics below cover a key growth driver, an emerging opportunity, a notable trend, and a central challenge specific to this market.

Key Growth Driver: Rise in Cancer Cases

The steadily growing global population of cancer patients and survivors is a central driver of MRD testing demand, as clinicians increasingly use MRD results to gauge how well a patient has responded to therapy. With millions of cancer survivors now living in the U.S. alone, and traditional methods struggling to detect residual disease at very low cell concentrations, patients and providers are turning to MRD testing for the treatment-accuracy gains it offers.

Emerging Opportunity: Liquid Biopsy and Expansion into Solid Tumors

MRD testing has historically centered on blood cancers, but researchers are actively developing liquid biopsy-based MRD tests for solid tumors such as lung, breast, and colorectal cancer. Because liquid biopsy relies on a simple blood draw rather than invasive tissue sampling, its successful commercialization for solid tumors represents a substantial opportunity to extend MRD testing into a much larger patient population.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market 

Market Trend: AI-Assisted Bioinformatics and Relapse Prediction

As MRD testing generates increasingly complex genomic data, AI and bioinformatics tools are being used to interpret results faster, flag subtle cancer-related signals, and predict relapse risk from MRD and patient data together. This trend is reducing laboratory turnaround times and is expected to become more central to MRD platforms as sequencing volumes continue to grow.

Key Challenge: High Cost and Limited Reimbursement

MRD testing remains an expensive procedure that requires sophisticated equipment, skilled personnel, and often serial testing over time, limiting accessibility in lower-income settings and smaller laboratories. Reimbursement policies also vary by cancer type and testing methodology, and newer technologies may lack the documentation needed for insurance coverage, together restraining broader adoption of MRD as a first-line diagnostic tool.

How Is AI Impacting the Minimal Residual Disease (MRD) Market?

AI is playing a growing, if still developing, role in the MRD market. It can analyze large MRD datasets faster than manual review and improve interpretation of results, helping identify subtle cancer-related signals that would otherwise be difficult to detect. AI also supports faster analysis of NGS and other complex molecular testing data, while machine-learning models are being explored to predict relapse risk by combining MRD results with broader patient data. As adoption of AI-driven automation expands, it may help reduce laboratory workload and improve the overall efficiency of MRD testing.

Which Market Segments Are Gaining Momentum?

By detection target, leukemia led the market in 2025 given the high incidence of blood cancers, while solid tumors are set to grow fastest as ctDNA-based liquid biopsy testing expands into colorectal, lung, and breast cancer applications; lymphoma and multiple myeloma also continue to see steady double-digit growth as MRD negativity gains traction as a clinical trial endpoint. By test technique, flow cytometry held the largest share in 2025 owing to its sensitivity, speed, and broad clinical accessibility, while next-generation sequencing is growing fastest given its ultra-sensitive, genome-wide, and multi-cancer capabilities, and PCR continues to see solid adoption for its established use and rapid turnaround. By end user, hospitals and specialty clinics accounted for the largest share given their broad cancer patient base, while diagnostic laboratories are expanding fastest as hospitals increasingly outsource specialized MRD testing to scalable, technology-focused reference labs.

What Is Happening Across Regional Markets?

North America led the MRD market in 2025, supported by strong patient and physician awareness of screening benefits and widespread adoption of advanced testing technologies in the U.S. and Canada. Asia Pacific is projected to grow fastest through 2034 as rising hematologic cancer incidence, changing lifestyles, aging populations, and improving diagnostic capability expand the addressable patient population, with India in particular benefiting from rapid growth in molecular-diagnostics infrastructure and genomic testing capacity. Europe continues to see steady growth backed by advanced healthcare infrastructure and a growing base of clinical cancer research, while Latin America and the Middle East & Africa are seeing gradual gains as private healthcare investment and specialized cancer-testing infrastructure expand.

How Is the Competitive Landscape Changing?

The MRD market is competitive, bringing together diagnostic companies, genomics firms, and specialized laboratories that differentiate through test accuracy, expansion into solid tumors, and liquid-biopsy innovation. Larger companies benefit from broad laboratory networks and established regulatory clearances, such as Adaptive Biotechnologies' FDA-cleared clonoSEQ assay, while specialized players compete through innovative NGS, PCR, and personalized MRD testing platforms, often backed by strategic partnerships with hospitals, pharmaceutical companies, and research institutions.

Key companies covered in this analysis include:

• Adaptive Biotechnologies
• Natera, Inc.
• Guardant Health
• Hoffmann-La Roche Ltd.
• QIAGEN
• Sysmex Corporation
• NeoGenomics Laboratories
• Bio-Rad Laboratories
• Invivoscribe, Inc.
• Quest Diagnostics
• Mission Bio
• Cergentis B.V.
• ARUP Laboratories
• Inivata
• ArcherDX (Invitae)

Future Market Perspective

The outlook for the Minimal Residual Disease Testing market is positive, underpinned by continued advances in NGS, liquid biopsy, and ctDNA-based technologies. The market is expected to extend beyond blood cancers into solid tumors such as lung, breast, and colorectal cancer, with MRD testing becoming more deeply embedded in clinical trials, drug development, and personalized treatment decisions. Greater standardization and improved reimbursement are likely to further accelerate adoption through 2034.

More Trending Latest Reports By Polaris Market Research:

Food Service Equipment Market

Cigarette Paper Market

Quillaia Extracts Market

Diffractive Optical Elements Market

Fermentation Chemicals Market

Fermentation Chemicals Market

Prebiotic Ingredient Market

Castrate-Resistant Prostate Cancer Market

Digital Radiography Market